Genmab (GMAB) reported that worldwide net trade sales of Darzalex – daratumumab -, including sales of the subcutaneous product, as reported by J&J were $3.67B in Q3 2025. Net trade sales were $2.088B in the U.S. and $1.584B in the rest of the world.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Sell Rating on Genmab A/S: Strategic Moves and Financial Challenges Ahead
- Genmab price target raised to DKK 2,000 from DKK 1,900 at Deutsche Bank
- Genmab price target raised to $49 from $46 at Truist
- Genmab price target raised to $40 from $36 at H.C. Wainwright
- Genmab A/S Updates Articles of Association to Enhance Growth Strategy